title: Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.
abstract: BACKGROUND
  Bevacizumab is a humanized IgG1 monoclonal antibody against VEGF. Because infusion-related hypersensitivity reactions (HSRs) are a concern with monoclonal antibodies, initial phase 1 trials used a 90-, 60-, then 30-min initial infusion sequence. We evaluated the impact of a shortened bevacizumab infusion (10 min) on toxicity in nonsmall cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Consecutive patients with stage IV NSCLC eligible for anti-VEGF therapy received a platinum doublet plus bevacizumab 7.5 mg/kg infused over 10 min, every 3 weeks, in the outpatient setting. Blood pressure was monitored at home twice daily, and other toxicities (HSRs and proteinuria) were monitored at each treatment administration.
  
  
  RESULTS
  Bevacizumab was given as a 10 min infusion in 55 patients (group A), and using the standard sequence in another 36 patients (group B). Hypertension (grade ≥ 2) was observed in 18/55 (32.7%) patients in group A and 13/36 (38.9%) patients in group B (p = 0.77). Similarly, no difference was seen regarding the incidence of grade ≥ 2 proteinuria (12.7% vs. 19.4%, p = 0.39), arterial thrombo-embolic events (0 in each group) or venous thromboembolic events (1.8% vs. 8.3%, p = 0.29).
  
  
  CONCLUSIONS
  Our data suggest that bevacizumab 7.5 mg/kg can be safely infused over 10 min in unselected NSCLC patients despite their cardio-vascular and respiratory comorbidities, saving time for both patients and caregivers.
authors: Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors, Paris, France. olivier.mir@cch.aphp.fr
authors: Olivier
authors: O
authors: Mir
authors: Jérôme
authors: J
authors: Alexandre
authors: Romain
authors: R
authors: Coriat
authors: Stanislas
authors: S
authors: Ropert
authors: Pascaline
authors: P
authors: Boudou-Rouquette
authors: Thach
authors: T
authors: Bui
authors: Jeanne
authors: J
authors: Chapron
authors: Jean-Philippe
authors: JP
authors: Durand
authors: Daniel
authors: D
authors: Dusser
authors: François
authors: F
authors: Goldwasser
references: J Gastrointest Cancer. 2012 Jun;43(2):244-8
references: 21197622
references: Acta Oncol. 2010 Apr;49(3):395-6
references: 20001495
references: J Clin Oncol. 2001 Feb 1;19(3):843-50
references: 11157038
references: J Clin Oncol. 2007 Jul 1;25(19):2691-5
references: 17602073
references: Bull Cancer. 2009 Oct;96(10):951-60
references: 19734117
references: Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24
references: 14613032
references: Dig Liver Dis. 2011 Mar;43(3):248-9
references: 21145299
references: J Clin Oncol. 2001 Feb 1;19(3):851-6
references: 11157039
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435